The Board acknowledges the Strategy, Investment and Impact Committee’s (the “SIIC”) plan to develop recommendations for Board consideration at its March 2015 meeting on the Global Fund’s role in funding treatment of co-infections and co-morbidities of HIV/AIDS, tuberculosis and malaria, and directs the Secretariat to engage and collaborate with partners to support the SIIC’s development of such recommendations.
As an interim measure until there is an outcome to those deliberations, where there is a currently approved budget for Hepatitis C virus (“HCV”) treatment within an existing Global Fund grant, the Global Fund may continue to fund such treatment up to the approved budget amount, as set forth in GF/B32/22, and may otherwise permit continuation of Global Fund funded HCV treatment programs during this interim period with new grants in these countries up to previously approved budgeted levels.
The Board encourages partners to finance broader and additional HCV treatment needs, including those identified within Global Fund grant programs.
The Board acknowledges the close working relationship and collaboration among the Global Fund, UNITAID and other partners on market-shaping activities, including the expansion of access to HCV treatments.
Global Fund and Hepatitis C Treatment
download in English
Decision Superseded by:
Policy on Co-infections and Co-morbidities